留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

重型再生障碍性贫血治疗进展

季艳萍 孙自敏

季艳萍, 孙自敏. 重型再生障碍性贫血治疗进展[J]. 器官移植, 2020, 11(2): 293-297, 310. doi: 10.3969/j.issn.1674-7445.2020.02.018
引用本文: 季艳萍, 孙自敏. 重型再生障碍性贫血治疗进展[J]. 器官移植, 2020, 11(2): 293-297, 310. doi: 10.3969/j.issn.1674-7445.2020.02.018
Ji Yanping, Sun Zimin. Treatment progress of severe aplastic anemia[J]. ORGAN TRANSPLANTATION, 2020, 11(2): 293-297, 310. doi: 10.3969/j.issn.1674-7445.2020.02.018
Citation: Ji Yanping, Sun Zimin. Treatment progress of severe aplastic anemia[J]. ORGAN TRANSPLANTATION, 2020, 11(2): 293-297, 310. doi: 10.3969/j.issn.1674-7445.2020.02.018

重型再生障碍性贫血治疗进展

doi: 10.3969/j.issn.1674-7445.2020.02.018
基金项目: 

国家自然科学基金 81470350

中央高校基本科研业务费专项资金 WK9110000001

详细信息
    作者简介:

    季艳萍,女,1993年生,硕士研究生,研究方向为造血干细胞移植治疗血液系统疾病,Email:18772956007@163.com

    通讯作者:

    孙自敏,女,1956年生,教授,主任医师,研究方向为造血干细胞移植及疑难血液病的诊治,Email:zmsun_vip@163.com

  • 中图分类号: R617, R556.5

Treatment progress of severe aplastic anemia

More Information
  • 摘要: 重型再生障碍性贫血(SAA)是一类少见的骨髓造血功能衰竭性疾病,与患者体内毒性T淋巴细胞为主的免疫功能紊乱、造血微环境的异常和造血干细胞的损伤相关。SAA起病急、进展快、病情重且致死率高,需快速并稳定地恢复患者造血功能。本文就免疫抑制剂疗法(IST)治疗SAA、同胞人类白细胞抗原(HLA)全相合异基因造血干细胞移植(allo-HSCT)治疗SAA、替代供者造血干细胞移植治疗SAA、非血缘脐血造血干细胞移植治疗SAA等方面的治疗进展进行综述。

     

  • [1] HOSOKAWA K, MURANSKI P, FENG X, et al. Memory stem T cells in autoimmune disease: high frequency of circulating CD8+ memory stem cells in acquired aplastic anemia[J]. J Immunol, 2016, 196(4):1568-1578. DOI: 10.4049/jimmunol.1501739.
    [2] KILLICK SB, BOWN N, CAVENAGH J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia[J]. Br J Haematol, 2016, 172(2):187-207. DOI: 10.1111/bjh.13853.
    [3] 聂玲辉, 伍志勇, 朱晓光, 等.重型再生障碍性贫血的研究进展[J].分子影像学杂志, 2017, 40(1):85-89. DOI: 10.3969/j.issn.1674-4500.2017.01.25.

    NIE LH, WU ZY, ZHU XG, et al. Research progress of severe aplastic anemia[J]. J Mol Imaging, 2017, 40(1):85-89. DOI: 10.3969/j.issn.1674-4500.2017.01.25.
    [4] MEDINGER M, DREXLER B, LENGERKE C, et al. Pathogenesis of acquired aplastic anemia and the role of the bone marrow microenvironment[J]. Front Oncol, 2018, 8:587. DOI: 10.3389/fonc.2018.00587.
    [5] 苏雁.重型再生障碍性贫血的非移植治疗进展[J].中国小儿血液与肿瘤杂志, 2017, 22(4):169-172.DOI:10. 3969/j.issn.1673-5323.2017.04.001.

    SU Y. Research progress of non-transplantation treatments of severe aplastic anemia[J]. J Chin Pediatr Blood Cancer, 2017, 22(4):169-172. DOI:10.3969/j.issn. 1673-5323.2017.04.001.
    [6] 叶蕾, 井丽萍, 杨文睿, 等.围免疫抑制治疗期感染对重型再生障碍性贫血患者血液学反应及生存的影响[J].中华血液学杂志, 2015, 36(8):670-675.DOI: 10.3760/cma.j.issn.0253-2727.2015.08.009.

    YE L, JING LP, YANG WR, et al. Effects of peri-immunosupressive therapy period infection on hematologic response and survival of severe aplastic[J]. Chin J Hematol, 2015, 36(8):670-675. DOI: 10.3760/cma.j.issn.0253-2727.2015.08.009.
    [7] PIERRI F, DUFOUR C. Management of aplastic anemia after failure of frontline immunosuppression[J]. Expert Rev Hematol, 2019, 12(10):809-819. DOI: 10.1080/17474086.2019.1645003.
    [8] BUSSEL J, KULASEKARARAJ A, COOPER N, et al. Mechanisms and therapeutic prospects of thrombopoietin receptor agonists[J]. Semin Hematol, 2019, 56(4):262-278. DOI: 10.1053/j.seminhematol.2019.09.001.
    [9] SANZ J, MOSCARDÓ F, MONTORO J, et al. Partial T cell-depleted peripheral blood stem cell transplantation from HLA-identical siblingdonors for patients with severe aplastic anemia[J]. Biol Blood Marrow Transplant, 2020, 26(1):83-87. DOI: 10.1016/j.bbmt.2019.08.020.
    [10] MARSH JCW, RISITANO AM, MUFTI GJ. The case for upfront HLA-matched unrelated donor hematopoietic stem cell transplantation as a curative option for adult acquired severe aplastic anemia[J]. Biol Blood Marrow Transplant, 2019, 25(9):e277-e284. DOI: 10.1016/j.bbmt. 2019.05.012.
    [11] YANG S, YUAN X, MA R, et al. Comparison of outcomes of frontline immunosuppressive therapy and frontline haploidentical hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched sibling donor[J]. Biol Blood Marrow Transplant, 2019, 25(5):975-980. DOI: 10.1016/j.bbmt.2019.01.017.
    [12] FATOBENE G, STORER BE, SALIT RB, et al. Disability related to chronic graft-versus-host disease after alternative donor hematopoietic celltransplantation[J]. Haematologica, 2019, 104(4):835-843. DOI: 10.3324/haematol.2018.202754.
    [13] OLNES MJ, SCHEINBERG P, CALVO KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia[J]. N Engl J Med, 2012, 367(1):11-19. DOI: 10.1056/NEJMoa1200931.
    [14] TOWNSLEY DM, SCHEINBERG P, WINKLER T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia[J]. N Engl J Med, 2017, 376(16):1540-1550. DOI: 10.1056/NEJMoa1613878.
    [15] DE BRUIN AM, VOERMANS C, NOLTE MA. Impact of interferon-γ on hematopoiesis[J]. Blood, 2014, 124(16):2479-2486. DOI: 10.1182/blood-2014-04-568451.
    [16] 杨世伟, 马荣军, 赵娟娟, 等.不同方式异基因造血干细胞移植一线治疗儿童及青少年重型再生障碍性贫血的比较[J].中华血液学杂志, 2018, 39(3):184-189. DOI: 10.3760/cma.j.issn.0253-2727.2018.03.003.

    YANG SW, MA RJ, ZHAO JJ, et al. Comparison of different styles of allogeneic hematopoietic stem cell transplantation as first-line treatment treated with severe aplastic anemia in children and adolescents[J]. Chin J Hematol, 2018, 39(3):184-189. DOI: 10.3760/cma.j.issn.0253-2727.2018.03.003.
    [17] XU LP, JIN S, WANG SQ, et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant[J]. J Hematol Oncol, 2017, 10(1):10-25. DOI: 10.1186/s13045-017-0398-y.
    [18] DEZERN AE, ZAHURAK M, SYMONS H, et al. Alternative donor transplantation with high-dosepost-transplantation cyclophosphamide for refractory severe aplastic anemia[J]. Biol Blood Marrow Transplant, 2017, 23(3):498-504. DOI: 10.1016/j.bbmt.2016.12.628.
    [19] LIU HL, SUN ZM, GENG LQ, et al. Unrelated cord blood transplantation for newly diagnosed patients with severe acquired aplastic anemia using a reduced-intensity conditioning: high graft rejection, but good survival[J]. Bone Marrow Transplant, 2012, 47(9):1186-1190. DOI: 10.1038/bmt.2011.251.
    [20] MOALIC-ALLAIN V. Medical and ethical considerations on hematopoietic stem cells mobilization for healthy donors[J]. Transfus Clin Biol, 2018, 25(2):136-143. DOI: 10.1016/j.tracli.2018.02.004.
    [21] PEFFAULT DE LATOUR R, CHEVRET S, JUBERT C, et al. Unrelated cord blood transplantation in patients with acquired refractory aplastic anemia: a nationwide phase Ⅱ study[J]. Blood, 2018, 132(7):750-754. DOI: 10.1182/blood-2018-01-829630.
    [22] PEFFAULT DE LATOUR R, PURTILL D, RUGGERI A, et al. Influence of nucleated cell dose on overall survival ofunrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation[J]. Biol Blood Marrow Transplant, 2011, 17(1):78-85. DOI: 10.1016/j.bbmt.2010.06.011.
    [23] PEFFAULT DE LATOUR R. Transplantation for bone marrow failure: current issues[J]. Hematology Am Soc Hematol Educ Program, 2016(1):90-98. DOI: 10.1182/asheducation-2016.1.90.
    [24] CLÉ DV, ATTA EH, DIAS DSP, et al. Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study[J]. Ann Hematol, 2018, 97(11):2039-2046. DOI: 10.1007/s00277-018-3416-4.
    [25] ZENG Y, WANG S, WANG J, et al. Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem celltransplantation: a large-sample study from China[J]. Sci Rep, 2018, 8(1):2479. DOI: 10.1038/s41598-018-20853-9.
  • 加载中
计量
  • 文章访问数:  153
  • HTML全文浏览量:  154
  • PDF下载量:  15
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-12-23
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2020-03-15

目录

    /

    返回文章
    返回